AbbVie Inc. (ABBV)
Healthcare · Drug Manufacturers - General · Data as of 2026-09-01
Bottom line
ABBV is trading at a premium to its history, in the middle of its recent price range, and recent volume suggests money flowing in. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Trading at a premium (Red)
ABBV trades at 72× earnings, above its own 5-year average of 48× and above similar healthcare companies we track (29×, 52 peers). Investors are currently paying more per dollar of earnings than usual. Its free-cash-flow yield is about 4.4%. Its current multiple sits around the 65th percentile of its own last five years — toward the high end of its own range.
Price zones — In the middle of its recent range (Yellow)
At $259.99, the stock sits between its recent support and resistance levels. Over the past year ABBV has traded between $190.75 and $267.47; its historical support zone sits near $253.17 and resistance near $267.47. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $190.75–$267.47 · 50-day average $253.17 · 200-day average $227.94
Money flow — Money is flowing in (Green)
Recent trading in ABBV shows more volume on rising days than falling days, a pattern often described as accumulation. Volume on up days has been about 1.1× volume on down days over the last 30 sessions.
About the company
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients.
一句话结论
ABBV 相对自身历史处于溢价水平，处于近期价格区间的中部，近期成交量显示资金正在流入。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于溢价水平
ABBV 目前的市盈率为 72×，高于其自身 5 年平均的 48×，并且高于我们追踪的同类Healthcare公司（29×，52 家）。投资者目前为每一美元盈利付出的价格高于以往。其自由现金流收益率约为 4.4%。它当前的估值倍数大约位于自身过去五年分布的第 65 百分位——处于自身区间的偏高位置。
价格区间 — 处于近期区间的中部
目前价格为 $259.99，位于其近期的支撑位与阻力位之间。过去一年 ABBV 的价格在 $190.75 到 $267.47 之间波动；其历史支撑区在 $253.17 附近，阻力区在 $267.47 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 资金正在流入
ABBV 近期上涨日的成交量高于下跌日，这种形态常被称为吸筹。过去 30 个交易日，上涨日的成交量约为下跌日的 1.1×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.